Eton Pharmaceuticals, Inc. (ETON)

NGM – Real vaqt narxi. Valyuta: USD

29.71

-0.13 (-0.44%)

Yopilishda: May 12, 2026, 4:00 PM EDT

29.85

+0.14 (0.47%)

Bozor oldidan: May 13, 2026, 5:28 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Eton Pharmaceuticals, Inc. (ETON)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

Eton Pharmaceuticals Announces CFO Succession Plan

Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?

Recent Price Trend in Eton Pharmaceuticals (ETON) is Your Friend, Here's Why

Videolar

No Data

Press-relizlar

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

Eton Pharmaceuticals Announces CFO Succession Plan

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

Search stocks

Eton Pharmaceuticals, Inc. (ETON)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

Eton Pharmaceuticals Announces CFO Succession Plan

Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?

Recent Price Trend in Eton Pharmaceuticals (ETON) is Your Friend, Here's Why

Videolar

No Data

Press-relizlar

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

Eton Pharmaceuticals Announces CFO Succession Plan

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution